loader2
Partner With Us NRI

Global Health Ltd share Price Today

Company details

931.00
970.90
426.15
1,028.00
6M Return 53.86%
1Y Return 100.78%
Mkt Cap.(Cr) 25,089.34
Volume 325,504
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 325,504

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Healthcare Facilities company Global Health announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Total income of Rs 8,647 million; growth of 24.5% YoY
    • EBITDA of Rs 2,336 million; growth of 35.7% YoY
    • EBITDA margins improved from 24.8% in Q2FY23 to 27% in Q2FY24
    • Profit after tax was at Rs 1,252 million; up by 46.1% YoY
    • Average Occupied bed days increased by 17.8% YoY, representing an occupancy of 64.9% in Q2FY24
    • ARPOB grew by 4.8% YoY to Rs 61,003; In-patient count increased by 19.4% and Out-patient count increased by 23.2% YoY
    • Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 27% in Q2FY23 to 31% in Q2FY24 amounting to Rs 2,643 million. Developing Hospital EBITDA share increased from 33% in Q2FY23 to 38% in Q2FY24 amounting to Rs 897 million
    • Matured hospitals registered a strong growth of 19.5% YoY and EBITDA growth of 32.8% YoY amounting to Rs 6,064 million and Rs 1,545 million respectively
    • Revenue from international patients increased by 20% YoY to Rs 507 million driven by increased volumes and realization
    • OPD pharmacy business continues to register strong growth. Revenue increased by 39% YoY from Rs 215 million in Q2FY23 to Rs 298 million in Q2FY24
  • H1FY24:
    • Total income of Rs 16,592 million; growth of 25.6% YoY
    • EBITDA of Rs 4,329 million; growth of 38.0% YoY
    • EBITDA margins improved from 23.7 % in H1FY23 to 26.1% in H1FY24
    • Profit after tax of Rs 2,272 million; growth of 57.3% YoY
    • Average Occupied bed days increased by 17.1% YoY, representing an occupancy of 61.5% in H1FY24
    • ARPOB grew by 5.9% YoY to Rs 62,011 in H1FY24; In-patient volume increased by 19.4% and Out-patient volume increased by 20.5% YoY in H1FY24
    • incurred Capex of Rs 1,276 million incurred during H1FY24, out of which Rs 308 million was incurred towards Noida hospital

Commenting on Q2FY24 results, Pankaj Sahni, Group CEO and Director said, “We are pleased to report that the Company continues to deliver strong year-on-year and sequential growth across key performance indicators. The growth was seen at both matured and developing units, driven by higher patient volumes, underpinned by bed growth, doctor additions, and technology advancement. During the quarter, we received NABH accreditation for Patna Hospital, this accreditation reflects our commitment to deliver the highest quality healthcare in underserved markets. Our Noida hospital construction is on track and is expected to commence operations by FY2025 the end. As we move forward, we remain committed to executing our planned strategies while maintaining the highest quality and ethics as demonstrated by our ‘Medanta Model of Care’.

 

 

Result PDF

View Other Company Results

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Global Health Ltd Stocks COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 2,428.21 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 20,486.67 41,311.63
LAST 3M 59,182.99 18,817.17
LAST 6M 99,630.35 93,158.70
LAST 12M 166,983.77 138,194.89

Global Health Ltd Information

Stock PE (TTM)
61.23
Promoter Holding
33.06%
Book Value
98.8771
ROCE
16.49%
ROE
16.13%
Description
  • Global Health Limited (GHL) was incorporated as `Global Health Private Limited` on August 13, 2004 at New Delhi, India as a Private Limited Company. The Company converted into a Public Limited Company and name of the Company was changed to `Global Health Limited` dated August 11, 2021 issued by the RoC. Presently, the Company is engaged in the business of providing healthcare services. The Company was founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon. The Company is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India in terms of bed capacity with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urologoly. Under the "Medanta" brand, it has a network of 5 hospitals currently in operation including, Gurugram, Indore, Ranchi, Lucknow and Patna and one hospital in Noida, which is under construction. As at June 30, 2022, the Company provide healthcare services in over 30 medical specialties and is engaged over 1,300 doctors led by experienced department heads and, spanning an area of 4.7 million sq. ft., their operational hospitals have 2,467 installed beds to serve Indian and international patients. In November 2009, the Company opened its flagship hospital in Gurugram. In 2015, its subsidiary, Global Health Patliputra Private Limite (GHPPL), entered into a Concession Agreement with Governor of Bihar for the development, operation and maintenance of a proposed hospital on public-private partnership at Patna. In 2019, it commenced operations of new hospital at Lucknow. In 2020, Patna hospital`s outpatient department facility was launched and the inpatient department facility of its Patna hospital was inaugurated in October 2021, which commenced operations during year 2022. The Company has taken in-house facility and operate pharmacies at its Gurugram, Lucknow, Indore and Ranchi hospitals as well as launched an outpatient department pharmacy at South Delhi clinic in year 2021 and launched outpatient department pharmacy at South Delhi clinic at Patna hospital in year 2022. As at June 30, 2022, it had 200 installed beds and employed over 50 doctors across key specialties such as neuroscience and cardiac sciences. Patna hospital had 228 installed beds and employed over 125 doctors as at June 30, 2022 and is designed to accommodate over 500 beds. In the Board Meeting dated 25 January 2021, the Board of Directors of the Holding Company have approved capital raising comprising of fresh issue and offer for sale of equity shares by the existing shareholders through an Initial Public Offering (IPO) The Company came out with a public issue during November, 2022 by raising Rs. 2205.57 crores through fresh issue amounting to Rs. 500 crores and offer for sale amounting to Rs. 1705.57 crores. The Company`s Lucknow hospital added 191 beds in FY23, including over 90 critical care beds. Lucknow Hospital further added 7 new OTs and have hired over 50 senior clinicians. Towards the end of FY 2023, Lucknow Hospital commissioned the Siemens Varian EDGE Radiation Oncology machine - the first in North India - as well as set up a dedicated e-ICU Command Centre to assist in remote critical care management. The Company`s Patna hospital added over 100 beds and 35 doctors in FY23. In FY23, the Company introduced a new 300- bed hospital project in Indore. It started Medanta Labs in January 2023. During the year 2022-23, GHL Pharma was incorporated as a wholly-owned subsidiary on June 29, 2022.

Registered Address

Medanta-Mediclinic, E-18 Defence Colony, New Delhi, New Delhi, 110024

Tel : 91-124-4834060
Email : compliance:medanta.org
Website : http://www.medanta.org
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543654
NSE Code : MEDANTA
Book Closure Date (Month) :
BSE Group : B
ISIN : INE474Q01031

FAQ’s on Global Health Ltd Shares

You can buy Global Health Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Global Health Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 08, 2023 03:56 PM the closing price of Global Health Ltd was ₹ 934.75.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 08, 2023 03:56 PM, the market cap of Global Health Ltd stood at ₹ 25,089.34.

The latest PE ratio of Global Health Ltd as of Dec 08, 2023 03:56 PM is 61.23

The latest PB ratio of Global Health Ltd as of Dec 08, 2023 03:56 PM is 0.11

The 52-week high of Global Health Ltd is ₹ 1,028.00 while the 52-week low is ₹ 426.15

Download Our App

market app
market app